This study investigates the effects of subtenon autologous platelet-rich plasma (PRP) injections on retinal structure and visual function in patients with advanced dry age-related macular degeneration (AMD). PRP is derived from the patient's own blood and contains growth factors that may support cell survival and tissue repair. These factors are thought to help reduce retinal cell loss and slow disease progression. Three PRP injections were administered to the better-seeing eye at 4-week intervals, while the fellow eye served as an untreated control. Participants were followed from baseline to 10 weeks (two weeks after the third injection). The aim is to compare changes in RPE atrophy area, photoreceptor loss, and visual function between treated and untreated eyes.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in Retina Pigment Epithelium Atrophy Area (mm²)
Timeframe: Baseline (Week 0) to 2 weeks after the third PRP injection (Week 10)
Retina Pigment Epithelium Atrophy Growth Rate (Square root transformed, mm/year)
Timeframe: Baseline (Week 0) to Week 10 (2 weeks after the third PRP injection)
Change in Photoreceptor Loss Area (mm²)
Timeframe: Baseline (Week 0) to Week 10 (2 weeks after the third PRP injection)
Photoreceptor Loss Growth Rate (Square root transformed, mm/year)
Timeframe: Baseline (Week 0) to Week 10 (2 weeks after the third PRP injection)